Patient-specific modeling of metabolic dysfunction in statin-induced myopathy using iPSC-derived myocytes

使用 iPSC 衍生的肌细胞对他汀类药物诱导的肌病代谢功能障碍进行患者特异性建模

• 批准号: 10531033
• 负责人: June-wha Rhee
• 金额: $ 15.36万
• 依托单位: BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-08-15 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10531033
• 关键词: Patient; specific; modeling; metabolic; dysfunction

Project Summary/Abstract Statins are the most widely used medication in reducing blood cholesterol and preventing coronary heart disease. However, adherence is poor; studies report fewer than half of patients take statins as prescribed. One of the main barriers in statin adherence is symptoms related to myopathy which include muscle discomfort, weakness, and rhabdomyolysis, a potentially life-threatening condition. Yet, the underlying mechanism of statin-induced myopathy (SIM) remains poorly understood due to 1) complex pleiotropic and myotoxic effects of statins, 2) limited accessibility of affected patients’ myocytes, and 3) lack of appropriate animal models to investigate the differential susceptibilities of statin toxicity. Previous clinical and scientific findings suggest off-target effects of statins in the mitochondria as the mechanism of SIM, but the results have not been validated in human studies. Recent advances in the generation of skeletal muscle cells (SkMCs) from human iPSCs present an unprecedented opportunity to model skeletal muscle diseases such as SIM. Herein, I propose to investigate the disease mechanisms of SIM by using a patient-specific iPSC platform. Specifically, I will test the central hypothesis that SIM is mediated via skeletal muscle-specific off-target effects resulting in mitochondrial redox imbalance, metabolic compromise and subsequent cell death. For this study, I will first characterize metabolic consequences of statins in iPSC-derived SkMCs and patient myocytes (Aim 1). I will then investigate the mechanism behind patient-specific differential myopathic susceptibility to statins by comparing iPSC-SkMCs derived from patients tolerant of statins to patients suffering from SIM (Aim 2). Finally, I will identify novel genes critical in the pathogenesis of SIM utilizing a genome-scale CRISPR interference screening technique by specifically silencing genes involved in statin toxicity and thereby conferring statin tolerance (Aim 3). The findings from this study will elucidate the molecular mechanism of SIM and facilitate the creation of precision medicine tools to enhance the diagnosis, prevention and treatment of SIM.

项目总结/文摘